Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma

Oncology Reports

Volumn 20, Issue 3, 2008, Pages 511-516

  Ohno, Yoshio ^a   Izumi, Miki ^a   Yoshioka, Kunihiko ^a   Ohori, Makoto ^a   Yonou, Hiroyuki ^a   Tachibana, Masaaki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Clear cell carcinoma; Kidney cancer; Tenascin C

Indexed keywords

TENASCIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; CELL NUCLEUS; CYTOPLASM; ENZYME IMMUNOASSAY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 54549086667     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000035     Document Type: Article

References (24)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
2. Maldazys JD and deKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 136: 376-379, 1986.
3. Campbell SC, Novic AC and Bukowski RM: Renal tumors. 9th edition, Saunders Elsevier, Philadelphia, 2007.
4. Bleumer I, Oosterwijk E, De Mulder P and Mulders PF: Immunotherapy for renal cell carcinoma. Eur Urol 44: 65-75, 2003.
5. Rini BI and Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043, 2005.
6. Orend G and Chiquet-Ehrismann R: Tenascin-C induced signaling in cancer. Cancer Lett 244: 143-163, 2006.
7. Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L and Kosmehl H: mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 203: 771-779, 2004.
8. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K and Haglund C: Tenascin-C expression correlates with prognosis in gastric cancer. Oncology 64: 245-250, 2003.
9. Kusagawa H, Onoda K, Namikawa S, Yada I, Okada A, Yoshida T and Sakakura T: Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer 77: 98-102, 1998.
10. Lohi J, Tani T, Laitinen L, Kangas L, Lehto VP and Virtanen I: Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 63: 442-449, 1995.
11. Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K and Morii S: Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res 55: 295-297, 1993.
12. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H and Mikuz G: Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 57: 927-931, 2004.
13. Juuti A, Nordling S, Louhimo J, Lundin J and Haglund C: Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol 57: 1151-1155, 2004.
14. Sugawara I, Hirakoshi J, Masunaga A, Itoyama S and Sakakura T: Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion Metastasis 11: 325-331, 1991.
15. Jahkola T, Toivonen T, von Smitten K, Blomqvist C and Virtanen I: Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 69: 445-447, 1996.
16. Kressner U, Lindmark G, Tomasini-Johansson B, Bergstrom R, Gerdin B, Pahlman L and Glimelius B: Stromal tenascin distribution as a prognostic marker in colorectal cancer. Br J Cancer 76: 526-530, 1997.
17. Yoshida T, Ishihara A, Hirokawa Y, Kusakabe M and Sakakura T: Tenascin in breast cancer development - is epithelial tenascin a marker for poor prognosis? Cancer Lett 90: 65-73, 1995.
18. Ishihara A, Yoshida T, Tamaki H and Sakakura T: Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1: 1035-1041, 1995.
19. Gotz B, Scholze A, Clement A, Joester A, Schutte K, Wigger F, Frank R, Spiess E, Ekblom P and Faissner A: Tenascin-C contains distinct adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons. J Cell Biol 132: 681-699, 1996.
20. Adams M, Jones JL, Walker RA, Pringle JH and Bell SC: Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 62: 3289-3297, 2002.
21. Shuch BM, Lam JS, Belldegrun AS and Figlin RA: Prognostic factors in renal cell carcinoma. Semin Oncol 33: 563-575, 2006.
22. Sotiriou C and Piccart MJ: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553, 2007.
23. Bild AH, Potti A and Nevins JR: Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6: 735-741, 2006.
24. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.